Populace Pharmacokinetic Analysis coming from First-in-Human Information with regard to HDAC Inhibitor, REC-2282 (AR-42), within Sufferers along with Solid Cancers and Hematologic Types of cancer: In a situation Study regarding Considering Smooth versus. Body Size Normalized Dosing.